Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics concerning potential securities fraud or unlawful business practices. The investigation follows two stock drops after the company disclosed safety concerns in its nomlabofusp studies for Friedreich’s Ataxia. On September 29, 2025, Larimar’s stock fell 33.66% to $3.38 per share after revealing anaphylaxis in seven participants, despite calling the data positive. Then on June 29, 2026, the stock fell 12.57% to $3.20 per share after the company reported anaphylaxis in 10 of 43 patients in new data and confirmed a rolling Biologics License Application submission.
Larimar Therapeutics IncSecurities fraud investigation and safety concerns in nomlabofusp studies causing stock drops.